NR4A1 and breast carcinoma: Recently, a CDK4/6 inhibitor combined with fulvestrant or aromatase inhibitor was shown to markedly increase PFS and overall survival (OS), and will become an upfront therapy for hormone receptor (HR)-positive breast cancer [13,14,15,16].